Earlier this morning, Net Element announced that PayOnline signed a new 3-year contract to process transactions for certain international dating networks, including AnastasiaDate, AmoLatina and AsianDate. Collectively, these networks receive more than 150 million unique visits annually and have more than 4 million registered users that spend more than 360 million hours on the sites per year.

Net Element currently manages, operates and is in the process of integrating the PayOnline group of companies pending closing of its previously announced acquisition initiative.

The contract with the majority owner of the dating networks, Social Discovery Ventures (“SDV”), is expected to achieve minimum net revenues to Net Element in the amount of $1.2 million over 3 years and a minimum transaction processing commitment of $300 million.

The contract underscores Net Element’s advantage as a global payments-as-a-service platform that facilitates cross-border transactions yet on-boards through a single interface.

SDV’s dating networks will use PayOnline’s state-of-the-art global online payments gateway and fraud-management tools to manage its international online transaction processing.

“The millions of international users on our premium dating networks require a reliable service able to process high volume, cross-border transactions using all forms of payments,” stated Anthony Volpe, Social Discovery Ventures chief marketing officer. “We selected Net Element because they met that need.”

“This contract win demonstrates our ability to quickly derive value from strategic acquisitions and partnerships,” added Oleg Firer, Net Element CEO. “As we emerge from a period of financial and business restructuring, we plan to see more such value driving developments as we progress into our growth phase.”

For more information on Net Element, visit www.netelement.com

IEG Holdings Corp. is a provider of online unsecured consumer loans in 13 states under the ‘Mr. Amazing Loans’ brand. In recent months, the company has leveraged this proven business model to record improved financial results. Since launching its online lending platform in July 2013, IEG has increased its cumulative loan value by well over 3,200 percent, exceeding $8 million in May. This rapid growth is being driven by the company’s continued state licensing expansion, which is expected to include an additional 12 states by the end of 2015, including California and Ohio. Following these efforts, IEG expects its lending coverage to encompass approximately 80 percent of the U.S. population.

In addition to its domestic growth, IEG has recently made strides toward expanding its presence in the global lending market. In December, the company announced the re-launch of lending in Australia under the ‘Mr. Amazing Loans’ brand, as well as detailing plans to add an additional 1.45 billion people to its lending network through a commitment to international development. In particular, IEG has highlighted Canada, United Kingdom, Philippines and India as expansion candidates because of their strong market demand and developed lending industry.

The company’s continued commitment to increasing its market share has provided a platform for tremendous revenue growth in recent quarters. In the first quarter of 2015, IEG recorded interest revenue of nearly $340,000, a year-over-year boost of more than 1,000 percent. Moving forward, this figure is expected to grow significantly in concert with the continued geographical expansion of IEG’s lending services.

In June, IEG took a step toward the future when it upgraded from the OTC market group’s OTC Pink tier to the OTCQB tier. The company will look to build on this progress in the future by potentially uplisting to the NASDAQ Global Markets. IEG announced the submittal of an application for this change in May.

“It is exciting to become an SEC reporting company, continue our rapid expansion… and achieve record loan volumes,” Paul Mathieson, chairman and chief executive officer of IEG, stated in a news release. “By late 2015, we hope to be in a position to offer loans in 25 states, covering approximately 25 million people.”

For prospective shareholders, IEG’s rapid growth since launching its lending platform just under two years ago makes the company an intriguing investment opportunity in the months to come.

For more information, visit www.investmentevolution.com

Synergy Resources Corp. is a domestic oil and natural gas exploration and production company operating in the Wattenberg Field of the Denver-Julesburg Basin in northeast Colorado. The company operates 308 wells throughout the region, in addition to having an ownership interest in nearly 300 net producing wells. Through these projects, Synergy has access to an estimated 40.3 million barrels of oil equivalent, according to a February report by independent oil and gas consulting firm Ryder Scott Company.

The Denver-Julesburg Basin has established itself as one of the most important producing areas in the country by consistently generating oil and gas since its discovery in 1901. The total value of past production from the region, if calculated in modern prices, would exceed $150 billion. For Synergy, the basin’s high level of predictability and high drilling success rate could provide the company with an opportunity to achieve rapid return on investment in the future.

During its fiscal second quarter of 2015, Synergy leveraged its position within the Wattenberg field to dramatically increase production. In addition to increasing year-over-year revenue by three percent, the company recorded a 98 percent year-over-year increase in overall production. Primarily, this spike was a result of Synergy’s December acquisition of a 5,040 acre leasehold in the Wattenberg Field, which provided access to 73 operating vertical wells, as well as non-operated working interests in 17 horizontal wells.

“Our growth in proved reserves is a result of the success of our operated horizontal drilling program, the performance of the horizontal wells in the Wattenberg Field, and proved reserves added as a result of our acquisition we completed in December,” William E. Scaff, co-chief executive officer of Synergy, stated in a news release.

In May, Synergy continued to expand its presence in the Denver-Julesburg Basin when it reached an agreement with its non-operating partner to purchase the remaining 35 percent working interest in the Greenhorn prospect, which is located in the northeast extension area of the basin.

“Over the past twelve months we have been pursuing a higher working interest in all of our operated assets both in the core of the Wattenberg Field and in the extension area,” Scaff continued. “This acquisition… is consistent with that objective.”

Despite a sharp decrease in commodity prices that’s persisted throughout the first six months of 2015, Synergy’s recent performance is a promising indication for prospective investors moving forward. Look for the company to leverage its established position within the Greater Wattenberg Field with the goal of encouraging sustainable returns in the years to come.

For more information, visit www.syrginfo.com

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of products to treat serious and life-threatening diseases. The company’s product pipeline includes two phase III product candidates. The first, Blisibimod, is currently being studied for the treatment of lupus, a chronic disease that causes a patient’s immune system to attack his or her own tissues and organs. The second, Sollpura™, is currently being studied as a novel pancreatic enzyme replacement therapy for the treatment of cystic fibrosis and related diseases.

In recent months, Anthera made major strides toward the eventual commercialization of these two groundbreaking drug candidates. In March, the company secured a research award of up to $3 million from Cystic Fibrosis Foundation Therapeutics, Inc. to support the manufacturing and clinical development of Sollpura.

“Support from Cystic Fibrosis Foundation Therapeutics speaks to the importance of developing [Sollpura] and the organization’s extensive clinical trials network will be indispensable as we advance this therapy,” Paul F. Truex, president and chief executive officer of Anthera, stated in a news release.

Earlier this month, the company made significant progress in the development of Blisibimod by reaching the target enrollment goal for its CHABLIS-SC1 phase III clinical trial. The results from this study, which are expected to be available in the second half of 2016, are anticipated to support the eventual market approval of Blisibimod for the treatment of lupus.

“Reaching our enrollment target for CHABLIS-SC1 ahead of schedule is an important accomplishment,” stated Dr. Colin Hislop, chief medical officer of Anthera. “The accelerated pace speaks to the importance of patient identification and selection in lupus treatment.”

When commercialized, these two products could provide Anthera with a strong platform to realize considerable growth within the biopharmaceutical industry. According to the Lupus Foundation of America, an estimated 1.5 million Americans, and at least five million people worldwide, suffer from some form of Lupus. Likewise, according to the Cystic Fibrosis Foundation, an estimated 30,000 Americans, and approximately 70,000 people worldwide, suffer from cystic fibrosis.

For prospective investors, Anthera’s continued progress toward commercialization of its two unique drug candidates makes the company an intriguing investment opportunity in the months to come.

For more information, visit www.anthera.com

Apollo Medical Holdings (OTC: AMEH) is a leading integrated healthcare company providing solutions to hospitals, health plans, physicians and other health providers that enable cost-effective, quality healthcare. The company utilizes integrated care solutions in order to identify and manage patients who are at-risk for chronic conditions. By coordinating care for these patients across multiple facilities, ApolloMed helps them reduce hospital admissions and avoid unnecessary emergency room visits, providing the means for reduced overall medical costs without sacrificing on quality of care.

Earlier this month, ApolloMed announced that its network of physicians had surpassed 1,000 providers. Through this network, the company is able to provide leading health management services to more than 40,000 of its own patients, as well as over 75,000 additional patients for its clients. The company’s network of dedicated hospitalists, nursing home physicians, clinic physicians, hospice care group and home health agency allow ApolloMed to provide care for some of the most complex and highest cost patients in the United States healthcare system.

Moving forward, ApolloMed is in a strong position to capitalize on the evolving landscape of the medical industry, particularly as it relates to value-based payments. In January, the U.S. Department of Health and Human Services (HHS) announced substantial changes to the way in which Medicare payments will be processed in the future. HHS set a goal of tying 30 percent of fee-for-service Medicare payments to quality or value through alternative payment models by the end of 2016. By the end of 2018, this change is expected to affect at least 50 percent of all Medicare payments. This announcement marked the first time in the history of the Medicare program that explicit goals for value-based payments have been set.

“Over the past three years, we have built a growing, robust network of physicians and an outcome-centric population health management platform that is at the forefront of the movement to value-based care,” Dr. Warren Hosseinion, chief executive officer of ApolloMed, stated in a news release. “We believe ApolloMed is well positioned to benefit from these transformative changes and sizable market growth over the next decade.”

For prospective shareholders, ApolloMed represents an opportunity to invest in an established player in the value-based medical market. With the recently announced shift in Medicare payment processing, the company’s developed and expanding network of medical group and accountable care organization physicians could provide a platform for increased revenues and, as a result, sustainable shareholder returns in the years to come.

For more information, visit www.apollomed.net

Heron Therapeutics, Inc. (NASDAQ: HRTX) is a biotechnology company focused on the development and commercialization of best-in-class pharmaceutical products that address major unmet medical needs. The company’s leading drug candidate, SUSTOL®, is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV), which affects approximately 75 percent of patients undergoing cancer treatment.

SUSTOL improves upon the current treatment options for CINV by utilizing Heron’s proprietary drug delivery platform, Biochronomer®. The company’s groundbreaking delivery technologies allow for sustained levels of drugs in systemic circulation, providing prolonged efficacy in a variety of potential applications. In clinical studies, Heron has demonstrated these benefits, with SUSTOL maintaining therapeutic drug levels for up to five days with a single subcutaneous injection.

In recent months, the company has taken significant steps toward the eventual commercialization of SUSTOL. In May, Heron announced the top-line results from its 900 patient phase III clinical study of the product candidate. According to these results, SUSTOL provided significantly higher rates of complete response than the test’s three-drug standard of care comparator group, demonstrating the overall efficacy and market potential of the candidate.

“[T]he results… further demonstrate the potential for SUSTOL to be the foundation of the new standard-of-care injectable anti-emetic regimen,” Barry D. Quart, chief executive officer of Heron, stated in a news release. “[W]e are planning for the commercial launch of SUSTOL, pending FDA approval.”

In addition to its progress with SUSTOL, Heron has also taken significant steps in the development of its second drug candidate, HTX-011, in recent weeks. Earlier this month, the company announced the initiation of a phase II clinical trial on the candidate for the prevention of post-operative pain. By effectively assisting patients in managing pain with a reduction in the use of opioids, as compared to the current standard of care, HTX-011 could provide Heron with an additional platform to realize continued growth in the future.

“We believe that HTX-011 has the potential to meet our core goal of developing best-in-class medicines with the potential to significantly improve the lives of patients,” continued Quart.

For prospective investors, Heron’s rapid progress toward the commercialization of its two leading drug candidates could provide a platform to realize substantial returns in the years to come.

For more information, visit www.herontx.com

American Locker Group, Inc. (OTC: ALGI) is a premier metal fabricator producing secure storage solutions under the American Locker and Canadian Locker brands. The company’s proprietary offerings include coin-operated security lockers, employee lockers and computer-controlled keyless systems. Leveraging over 75 years of industry expertise, ALGI stands apart from the competition as the only locker company that manufactures and controls its own distribution of non-duplicative keys, locks and cylinders. In total, the company has access to 16 million unique key patterns with which to work in the future.

The company’s current offerings include a vast selection of fully-configurable locker solutions. Recently, ALGI built upon the success of its iconic security lockers through the release of four innovative product offerings. The E-CBU locker system is an electronic locker targeted at libraries to allow for ATM-style distribution through the use of unique codes that can be tied to library cards. ALGI’s stackable Laptop Lockers are a space-saving approach to the storing, recharging and management of virtually all mobile technology devices. The Keyless Mini-Check® lockers are an innovative self-service design allowing for the storage of cell phones, wallets and keys. Finally, the company’s Envoy lockers are high-end, all-welded employee locker systems that are among the most rugged on the market.

In addition to lockers, ALGI is approved by the United States Postal Service as a manufacturer of multi-tenant mailboxes, including those installed at apartment and commercial buildings. Through this product category, the company addresses a sustainable market within the residential and commercial construction industries. Additionally, ALGI offers contract manufacturing services for precision fabricated sheet metal parts and enclosures for original equipment manufacturers and third-party customers.

Moving forward, ALGI is in a formidable position to build upon its established presence in the secure storage industry. In addition to selling its lockers directly to end users, the company utilizes a proven distribution network to sell its mailboxes. Through these two primary channels, ALGI will look to realize improved financial results in the years to come.

For more information, visit www.americanlocker.com

Callidus Software, Inc. (NASDAQ: CALD), doing business as CallidusCloud®, is the global leader in cloud-based sales, marketing, learning and customer experience solutions. The company’s proprietary suite of business offerings enables customers to identify leads, ensure proper distribution, enable sales forces, automate price quoting and streamline sales compensation in order to secure larger deals in less time. The company’s current customer base, which includes over 3,900 leading organizations in a variety of industries, relies on Callidus to optimize the lead-to-money process, opening the door for more revenue on an accelerated schedule.

By automating key portions of the marketing and sales processes, Callidus addresses the historical divide between the two vital business components. This groundbreaking approach to increased market share has helped the company achieve a host of recognition from the industry. In 2014, Callidus was awarded the ‘Cloud Computing Product of the Year Award’ by Cloud Computing magazine, as well as named ‘Best New Product – Financial Services’ at the International Business Awards℠, for its lead-to-money suite.

In the first quarter of 2015, Callidus built on this industry recognition by posting impressive financial results. Benefitting from the continued success of its product suite, the company recorded total revenue of $39.7 million, which was a substantial 28 percent year-over-year improvement, as well as a 37 percent year-over-year increase in SaaS revenue.

“I was pleased with our focus on execution in [the first quarter],” Leslie Stretch, president and chief executive officer of Callidus, stated in a news release. “In a busy quarter when we moved our headquarters and conducted a successful secondary offering we achieved record revenues and record recurring revenues. We beat both our cloud revenue growth percentage and total revenue guidance.”

Callidus is in a strong position to continue expanding upon its recent financial performance in the future. According to a report by MarketsandMarkets, the current value of the sales performance management (SPM) software market is estimated to be approximately $2.48 billion, and the sector is expected to grow to $5.62 billion by 2020. As businesses around the globe continue to shift from spreadsheets to the cloud, the company’s groundbreaking lead-to-money suite should present Callidus with an opportunity to promote strong market growth.

“The growth in the SPM market is driven by customers… who are looking to advance beyond traditional ineffective sales methods encumbered by spreadsheets,” Eric Brown, Callidus’s senior vice president of sales, stated. “The benefits of a modern, customer-centric selling solution are huge.”

For prospective shareholders, the near limitless market potential of the company’s software suite makes Callidus an intriguing investment opportunity moving forward.

For more information, visit www.calliduscloud.com

After the closing bell today, Dominovas Energy issued a press release that emphasizes and details the scope of the Power Africa Initiative announced earlier this week. Specifically, Dominovas Energy Corporation has been named as the first, and only, fuel cell company selected as a Private Sector Partner to President Barack Obama’s POWER AFRICA INITIATIVE. The Power Africa Initiative (PAI) is a multi-stakeholder partnership comprised of over 100 private sector partners. However, the Power Africa Initiative scope is, in fact, more expansive than the initial six countries previously reported. Power Africa is designed to provide support for all countries in sub-Saharan Africa, but in the first year offered intensive regulatory reform support and technical assistance to an initial set of six Power Africa focus countries – Ethiopia, Ghana, Kenya, Liberia, Nigeria, and Tanzania. These countries signed Memoranda of Understandings with Power Africa, which reflect the strong commitment of African governments to engage in policy and regulatory reform, and in particular to implement critical energy sector reforms. Through PAI, public sector agencies / entities maintain an express intent to nurture and accelerate private sector investment in sub-Saharan Africa’s power sector over the next several years.

Power Africa private sector partners represent the foundational support in building the regulatory, economic, and policy framework integral to meeting sub-Saharan Africa’s increasing demand for, and access to, electricity; and Dominovas Energy anticipates this partnership will continue to catalyze the resources and combined commitment of numerous U.S. government agencies, as well as the World Bank Group, AfDB, and many additional Power Africa partners, to facilitate Power Africa’s objectives, operations, and related sector investments. Detailed earlier this week, as a Power Africa private sector partner, Dominovas Energy will actively engage relevant U.S. agencies to fully employ the participating agencies’ tools to ensure any financing and capacity gaps that may exist can be addressed directly, specifically with respect to existing and incremental energy sector investments. These resources will allow Dominovas Energy to benefit from interagency efforts, by leveraging Power Africa’s tools including, but not limited to technical expertise and financing; while enhancing project bankability by implementing various risk mitigation tools.

Dominovas Energy’s President of its Africa Division, Emilio De Jesus, added, “With Power Africa’s commitment to the entire sub-Saharan Africa, it has set the stage for Dominovas Energy to complete sales cycles it began in earnest over two years ago with government officials of respective nations working closely with our company to realize a viable solution to their energy sector concerns.”

Over the next several years, as part of its commitment to Power Africa, Dominovas Energy intends to support and advance Power Africa goals by providing access to clean, reliable energy; partnering with specific universities in sub-Saharan Africa to train and hire local citizens as engineers and technicians, as necessary for the installation, service, and ongoing maintenance of the RUBICON™; and providing sub-Saharan countries with access to distributed, off-grid electricity on a multi-megawatt scale.

For more information on Dominovas Energy and its fuel cell technology, visit www.dominovasenergy.com

Let us hear your thoughts: Dominovas Energy Corp. Message Boards

Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The company’s leading product candidate, omadacycline, is the first in a new class of antibiotics derived from tetracyclines for use as a first-line monotherapy to treat serious bacterial infections when antibiotic resistance is a cause of concern.

In recent weeks, Paratek has continued to progress with the development of omadacycline. Earlier this month, the company initiated a phase III clinical trial of the drug candidate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). This study is meant to assess the efficacy and safety of omadacycline in treating ABSSSI, particularly as compared with current treatment option linezolid. The company’s second phase III trial on the drug candidate, which will begin enrolling patients later this year, will study its effectiveness in treating community-acquired bacterial pneumonia (CABP).

“The initiation of our registration trial for ABSSSI represents an important milestone for Paratek as a company,” Michael Bigham, chairman and chief executive officer of Paratek, stated in a news release. “We believe that omadacycline has the potential to become an important empiric monotherapy treatment option for patients suffering from ABSSSI, CABP, urinary tract infections and other bacterial infections when resistance is of concern.”

Upon commercialization, the potential market for Paratek’s novel antibiotic treatment is immense. According to a 2013 report by the Centers for Disease Control and Prevention, at least two million people in the United States become infected with bacteria that are resistant to conventional antibiotic treatment options each year, and an estimated 23,000 people die as a result of these infections.

In the first quarter of 2015, Paratek positioned itself to move forward with its omadacycline trials by securing approximately $71 million in funding through a common stock offering. With financing complete, the company will look to accelerate its existing clinical development plans, as well as adding a third potential indication in urinary tract infections (UTI), in the months to come. Based on current assumptions, Paratek’s cash and cash equivalents are expected to fund operations through mid-2017, which is expected to coincide with the availability of top-line data from the company’s CABP trial.

For prospective shareholders, the vast market potential of omadacycline and the current financial standing of Paratek combine to make the company an intriguing investment opportunity moving forward. As Paratek continues to make strides toward the commercialization of its innovative drug candidate, look for the company to clear the path for sustainable returns in the years to come.

For more information, visit www.paratekpharm.com